ABSTRACT
Cardiomyopathy (CMP) is a heritable genetic disorder. Protein-coding variants account for 20-30% of cases. The contribution of variants in non-coding DNA elements that regulate gene expression has not been explored. We performed whole-genome sequencing (WGS) of 228 unrelated CMP families. Besides pathogenic protein-coding variants in known CMP genes, 5% cases harbored rare loss-of-function variants in novel cardiac genes, with NRAP and FHOD3 being strong candidates. WGS also revealed a high burden of high-risk variants in promoters and enhancers of CMP genes in an additional 20% cases (Odds ratio 2.14, 95% CI 1.60-2.86, p=5.26×10−7 vs 1326 controls) with genes involved in α-dystroglycan glycosylation (FKTN, DTNA) and desmosomal signaling (DSC2, DSG2) specifically enriched for regulatory variants (False discovery rate <0.03). These findings were independently replicated in the Genomics England CMP cohort (n=1266). The functional effect of non-coding variants on transcription was functionally validated in patient myocardium and reporter assays in human cardiomyocytes, and that of novel gene variants in zebrafish knockouts. Our results show that functionally active variants in novel genes and in regulatory elements of CMP genes contribute strongly to the genomic etiology of childhood-onset CMP.
Competing Interest Statement
SWS is a scientific consultant to Population Bio, Deep Genomics Scientific Advisory Board, and his research patents held at the Hospital for Sick Children are licensed to Lineagen, and Athena Diagnostics. The other authors have no conflicts of interest to disclose.
Funding Statement
This work was funded by the Ted Rogers Centre for Heart Research to SM and JE. SM holds the Heart and Stroke Foundation of Canada Robert M Freedom Chair in Cardiovascular Science. SWS holds the GlaxoSmithKline Endowed Chair in Genome Sciences at the Hospital for Sick Children and the University of Toronto. PGM holds a Canada Research Chair Tier 2 in Noncoding Disease Mechanisms. PGM acknowledges the support of the Government of Canada New Frontiers in Research Fund, NFRFE 2018 01305. EO holds the Bitove Family Professorship of Adult Congenital Heart Disease. MM holds a Ramon y Cajal grant from the Spanish Ministery of Science and Innovation - RYC 2017 22249. WO is supported by funding from Fundacio La Marato - 321 C 2019. JB is funded by a Frans Van de Werf fellowship for clinical cardiovascular research, and by a senior clinical investigator fellowship of the FWO Flanders. KM was a National Science Foundation Graduate Research Fellow under grant no. DGE1144152 during the majority of the project. The 100000 Genomes Project is managed by Genomics England Limited, a wholly owned company of the Department of Health and Social Care. The 100000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection and use of human DNA and myocardial tissue from CMP cases through the Heart Centre Biobank Registry was approved by the Institutional Research Ethics Boards at the Hospital for Sick Children, Childrens Hospital of Eastern Ontario, Toronto General Hospital, London Health Sciences Centre, Kingston General Hospital, and Hamilton Health Sciences Centre.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequencing data are currently being deposited in the EGA European Genome-Phenome Archive and will be available for download upon approval by the Data Access Committee. Additional data generated or analyzed during this study are included in the supplementary information files, and additional raw data used for figures and results are available from the corresponding author on reasonable request. All computational tools used in this study are available as commercial or open-source software.
